[go: up one dir, main page]

WO2012019031A3 - Biomarkers for growth hormone disorders - Google Patents

Biomarkers for growth hormone disorders Download PDF

Info

Publication number
WO2012019031A3
WO2012019031A3 PCT/US2011/046632 US2011046632W WO2012019031A3 WO 2012019031 A3 WO2012019031 A3 WO 2012019031A3 US 2011046632 W US2011046632 W US 2011046632W WO 2012019031 A3 WO2012019031 A3 WO 2012019031A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
efficacy
biomarkers
assess
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046632
Other languages
French (fr)
Other versions
WO2012019031A2 (en
Inventor
John J. Kopchick
Diana Cruz-Topete
Jens Otto Lunde Jorgensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University filed Critical Ohio University
Publication of WO2012019031A2 publication Critical patent/WO2012019031A2/en
Publication of WO2012019031A3 publication Critical patent/WO2012019031A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed embodiments describe certain protein isoforms and their relation to the progress of a treatment for a growth hormone (GH) disorder. Embodiments include methods of monitoring the efficacy of a treatment for a GH disorder in a subject, including: (a) detecting one or more protein isoforms of transthyretin, haptoglobin α2, beta-hemoglobin, apoA-I, and complement C4B precursor; and (b) determining altered levels of said markers, the altered levels indicating efficacy of the treatment. In addition, one or more of the above biomarkers may be used to assess the efficacy of a treatment for acromegaly. In alternative embodiments, one or more of the above biomarkers may be used to assess the efficacy of GH treatments to GH deficient patients. In yet other embodiments, one or more of the above biomarkers may be used to assess GH misuse.
PCT/US2011/046632 2010-08-04 2011-08-04 Biomarkers for growth hormone disorders Ceased WO2012019031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37070910P 2010-08-04 2010-08-04
US61/370,709 2010-08-04

Publications (2)

Publication Number Publication Date
WO2012019031A2 WO2012019031A2 (en) 2012-02-09
WO2012019031A3 true WO2012019031A3 (en) 2012-05-10

Family

ID=45560077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046632 Ceased WO2012019031A2 (en) 2010-08-04 2011-08-04 Biomarkers for growth hormone disorders

Country Status (1)

Country Link
WO (1) WO2012019031A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
WO2010060935A1 (en) * 2008-11-26 2010-06-03 Merck Serono S.A. Compositions and methods for treating growth hormone deficiency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
WO2010060935A1 (en) * 2008-11-26 2010-06-03 Merck Serono S.A. Compositions and methods for treating growth hormone deficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRUZ-TOPETE, D. ET AL.: "Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity.", EUR. J. ENDOCRINOL., vol. 164, no. 3, February 2011 (2011-02-01), pages 157 - 167 *
DING, J. ET AL.: "Perspective: Proteomic approach to detect biomarkers of human growth hormone.", GROWTH HORMONE & IGF RESEARCH., vol. 19, 2009, pages 399 - 407, XP026390883 *

Also Published As

Publication number Publication date
WO2012019031A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012068516A3 (en) Low dose cannabinoid medicaments
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
BR112013029713A2 (en) vision disorder treatment method
WO2009158035A3 (en) Methods for dosing an activin-actriia antagonist and monitoring of treated patients
MX2013000674A (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
HK1259386A1 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
MX363213B (en) Anti-pcsk9 antibodies with ph-dependent binding characteristics.
WO2012148785A3 (en) Monitoring fluid volume for patients with renal disease
WO2016077366A8 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
WO2012109022A3 (en) Medical fluid delivery device programming
MX2012001716A (en) Biological markers for monitoring patient response to vegf antagonists.
HK1223319A1 (en) Methods for treating or preventing ophthalmological conditions
WO2012062925A3 (en) Compounds and methods for treating pain
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
HK1211831A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2012104620A3 (en) Wound prognosis
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
Chua et al. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2012068339A3 (en) Methods of treating cancer
WO2013057592A3 (en) Treatment of sickle cell disease
WO2015049390A3 (en) Kidney disease biomarker
WO2012019031A3 (en) Biomarkers for growth hormone disorders
WO2015036643A3 (en) Marker for predicting metastasis of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815336

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815336

Country of ref document: EP

Kind code of ref document: A2